Moderna is hoping its mRNA technology will succeed where other HIV vaccines failed
that it has begun dosing its first participants in Phase I clinical trials for an HIV vaccine that uses the same mRNA technology as the company’s COVID-19 vaccine.
Researchers will study 56 HIV-negative adults for six months. Forty-eight of the volunteers will receive at least one dose of the primary vaccine, 32 of whom will also receive the booster. The remaining eight will receive the booster vaccine alone. The first participants were just vaccinated at George Washington University School of Medicine and Health Sciences in Washington, D.C.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Troye Sivan's New Role Tackles the Realities of HIV Testing\u003cp\u003e\n\tSandra is PAPER's Contributing Editor-at-Large. She writes about sex and internet culture from her haunted house in Los Angeles. \u003ca href='https://www.instagram.com/sndrsng/' target='_blank'\u003esndrsng\u003c/a\u003e\n\u003c/p\u003e
Les mer »
Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipientsA third dose of mRNA vaccine may be necessary to protect recipients of organ transplants from COVID19 and produce effective antibody responses against SARSCoV2, suggests a new immunological analysis of kidney transplant recipients. ScienceTM
Les mer »
The FDA Just Approved Another COVID-19 VaccineIt's the second vaccine to receive full FDA approval.
Les mer »
COVID-19 live updates: Santa Clara Co. approves extra vaccine dose for immunocompromisedTransplant recipients, cancer patients and people with immunodeficiencies can now receive a third dose of the Moderna or Pfizer vaccine in Santa Clara County.
Les mer »
The staggering death toll of drug-resistant bacteriaGlobal survey shows that in 2019, antimicrobial resistance killed more people than HIV/AIDS or malaria.
Les mer »